Faculty


Indrakant Kumar Singh

Associate Professor

Molecular Biology & Health Informatics
Email: iksingh@acbr.du.ac.in

Dr. Indrakant K. Singh is abiomedical researcher and educator, currently serving as a Professor Associate at the Dr. B. R. Ambedkar Centre for Biomedical Research (ACBR), University of Delhi (DU). Before joining ACBR, he had served as a Professor and Head (TIC) in the Department of Zoology, Deshbandhu College, University of Delhi. He is a Fellow, Institute of Eminence, at the Delhi School of Public Health (DU), and his research integrates Molecular Biology and Health Informatics to address pressing health challenges.

Dr. Singh's laboratory focuses on cancer biology, rare genetic disorders, glaucoma and computational drug discovery, applying advanced bioinformatics, structural biology, and integrative omics approaches. His team has contributed to the development of small-molecule inhibitors for triple-negative breast cancer, colorectal cancer and neuroblastoma. He holds granted patents on innovative cancer diagnostic and therapeutic devices.In the field of rare diseases, Dr. Singh is spearheading efforts to understand and inhibit aberrant signaling in Fibrodysplasia Ossificans Progressiva (FOP), particularly focusing on ACVR1 mutations and RAR-gamma agonists for therapeutic applications. In Glaucoma,his lab focuses on identifying and targeting key molecular drivers involved in the disease's progression, particularly MAP4K4, ROCK2, and PDE4D.

With more than 95 peer-reviewed publications in esteemed journals such as Scientific Reports, International Journal of Molecular Sciences, International Journal of Biological Macromolecules, and Journal of Biomolecular Structure & Dynamics, Dr. Singh is recognized for his impactful contributions. He has also edited multiple academic books with Springer and CRC Press, and serves on editorial boards of various international journals.

His research has been consistently supported by leading agencies including ICMR, SERB,DHR, UGC & DU, and he maintains active collaborations with global institutions like USC Norris Cancer Centre(USA), St. Joseph University (USA), Palacky University (Czech Republic), and the Max-Planck Institute (Jena, Germany).Dr. Singh has mentored 10 doctoral and 5 postdoctoral scholars and remains committed to translating academic research into societal benefit.

Appointments:
  1. 1. 2025-Contd.:Associate Professor, Dr. B. R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi-110007, India

  2. 2. 2022-2025: Professor, Department of Zoology, Deshbandhu College,University of Delhi, Kalkaji, New Delhi-110019, India (On-lien)

  3. 3. 2023-2025: Head, Department of Zoology, Deshbandhu College,University of Delhi, New Delhi-110019, India

  4. 4. 2020-Contd.: Director, DBC I4 Centre and Research &Development Cell, Deshbandhu College, University of Delhi, Kalkaji, New Delhi-110019, India (On-lien)

  5. 5. 2023-Contd.: Visiting Professor, Norris Comprehensive Care Centre, Keck School of Medicine, University of Southern California, Los Angeles, USA.

  6. 6. 2022-Contd.: Fellow, Delhi School of Public Heath, Institute of Eminence, University of Delhi, Delhi-110007, India

  7. 7. 2019-2022: Associate Professor, Department of Zoology, Deshbandhu College,University of Delhi, Kalkaji, New Delhi-110019, India

  8. 8. 2019-2019: Visiting Scientist, Max-Planck Institute for Chemical Ecology, Germany

  9. 9. 2016-2017: Visiting Faculty / Raman Fellow, Department of Entomology,University of Kentucky, USA

  10. 10. 2013-2016: Visiting Faculty, Department of Computer Science (Bioinformatics) Jamia Millia Islamia, Delhi-110025, India

  11. 11. 2013-2014: Visiting/Guest Faculty, Department of Biotechnology, NSIT,University of Delhi, Dwarka, New Delhi- 110078, India

  12. 12. 2012-2019: Public Information Officer (PIO), Deshbandhu College,University of Delhi, Kalkaji, New Delhi-110019, India

  13. 13. 2009-2019: Assistant Professor, Department of Zoology, Deshbandhu College, University of Delhi, Kalkaji, New Delhi-110019, India

  14. 14. 2008-2008: Assistant Professor, Department of Zoology, Zakir Hussain Delhi College, University of Delhi, New Delhi-110002, India

  15. 15. 2005-2006: Assistant Professor, Department of Zoology, Hansraj College, University of Delhi, Delhi-110007, India

  16. 15. 2004-2005: Visiting Faculty, Department of Zoology, Kirori Mal College, University of Delhi, Delhi-110007, India

Award and Fellowship:
  1. 1. Long Term ICMR-DHR International Fellowship for Young Indian Biomedical Scientists, to work at Keck School of Medicine, University of Southern California, USA. (2019 &2023)

  2. 2. DHR Long Term National Fellowship for Training in Indian Institute at Translational Health Science and Technology Institute (THSTI), Faridabad, India. (2022)

  3. 3. Excellence Award for Teachers in Service 2021 (under 45 Years Age Category) from University of Delhi, India (2021)

  4. 4. Max-Planck Society Visiting Post-Doctoral Fellowship at Department of Molecular Ecology, Max-Planck Institute for Chemical Ecology, Jena, Germany (2019)

  5. 5. University Grant Commission (UGC)-Raman Post-doctoral Fellowship to work at University of Kentucky, Lexington, USA (2016)

  6. 6. Bharat Ratna Dr. A. P. J. Abdul Kalam Memorial "Best Teacher Awards" for contributions as teachers' research by Grace India Educational Charitable Trust, New Delhi, in the award ceremony at Hans Raj College, Delhi, India.

  7. 7. Best Researcher Awards, from Grace India Educational Charitable Trust, New Delhi, for research contribution, ceremony held at Hans Raj College, Delhi, India.

  8. 8. Nominated as an Indian Delegate for "International Program on "Reservation and Exploration of Herbal Medicine Resources for Asian Countries" funded by Ministry of Commerce, People's Republic of China, from August 19, 2015, to September 8, 2015.

  9. 9. Young Scientist Scheme Award (Start-up Grant), Science and Engineering Research Board (SERB), Department of Science & Technology, Govt. of India, New Delhi (2013)

  10. 10. Best participant in Life Science Category Prize in IFTF X2 workshops 2008 Organized by Institute for the Future, University Avenue, Palo Alto, California, USA

Patents Granted:
  1. 1. Indian Application No. 407726-001[2024]: Skin Cancer Prediction Device.

  2. 2. Indian Application No. 407728-001[2024]: Breast Cancer Drug Delivering Device.

  3. 3. Indian Application No. 419700-001[2024]: Plant Pathogen Detection Device.

  4. 4. Indian Application No. 407518-001[2024]: ML-Powered Freshness-Analyzer Device.

  5. 5. Indian Application No. 399494-001[2023]: Non-Invasive Oral Ulcer Diagnostic Device.

  6. 6. Indian Application No. 201911020282[2022] Method for identifying multidrug-resistant Mycobacterium tuberculosis strain (Under Examination)

  7. 7. US Patent Application No. 2/4687 [2022] Method for identifying multidrug-resistant Mycobacterium tuberculosis strain (Under Examination)

Projects:
  1. 1. 2024-27: Exploring the efficacy of promising RAR-Y agonists in pre-clinical (in-vitro and in-vivo) heterotopic ossification models for therapeutic implications in Fibrodysplasia ossificans progressive (FOP)(Principal Investigator) ICMR,Govt of India.

  2. 2. 2022-25: Immunotherapeutic role of Vitamin A (Retinoic acid) in the in vitro model of tuberculosis (Mentor)SERB, DST, Govt of India

  3. 3. 2021-24: Identification of the molecular mechanism of mechano-transduction pathways that act upstream of Hippo Pathway for treatment of breast cancer" (Principal Investigator) ICMR,Govt of India

  4. 4. 2020-23: Design, synthesis and biological evaluation of novel lead compounds for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) (Principal Investigator), DHR, Govt of India

  5. 5. 2019-23: Pharmacophore modeling to design novel inhibitors of MCL-1 as targeted therapy of human cancer (Mentor) DHR, Govt. of India

  6. 6. 2019-19: A comparative analysis of Jasmonoyl-L-isoleucine turn-over in the QTL mapping population of Nicotiana attenuata during Manduca sexta infestation (Visiting PDF Grant) MPICE, Germany

  7. 7. 2019-22: DBT Star College Project-Scheme (Principal Investigator/ Institutional Grant) DBT,Govt. of India

  8. 8. 2017-19: Design and development of novel inhibitors of AKRIC1 as potential lead candidates in the treatment of breast, cervical & endometrial cancer" (Mentor), DHR,Govt of India

  9. 9. 2016-17: dsRNA-conjugated nanoparticles for gene silencing in Aedes aegypti(UGC-Raman PDF), UGC,Govt of India

  10. 10. 2015-16: The impact of lifestyle change during adolescence on lifestyle chronic Diseases (Principal Investigator), University of Delhi, India

  11. 11. 2013-16: Identification and characterization of genes involved in defense against Spodoptera litura from Maize (Zea mays) (Principal Investigator), SERB, DST, Govt of India

Links:
  1. 1. Google Scholar: https://scholar.google.com/citations?user=Zf6FU-cAAAAJ&hl=en

  2. 2. Research Gate: https://www.researchgate.net/profile/Indrakant-Singh

  3. 3. ORCID ID: https://orcid.org/0000-0002-3211-8471

  4. 4. VIDWAN ID: https://vidwan.inflibnet.ac.in/profile/277541

  5. 5. WOS Researcher ID: AAC-7080-2022

  6. 6. Scopus Author ID: 24491218200

Vacant Research Positions:

Dr. Singh's lab is inviting applications from highly motivated, self-driven, disciplined individuals for the positions of training interns, lab assistants, Ph.D. scholars, and postdoctoral researchers.

If interested, please contact: iksingh@acbr.du.ac.in

Selected Recent Publications:
  1. 1. Ta, T. M., Reed, V. L., Gupta, S. R., Khan, M., Chandra, N., Dwyer, N., Singh, I.K.& Peethambaran, B. (2025). Novel macromolecule CPD4 suppresses cell proliferation and metastasis of triple-negative breast cancer by targeting ROR1 protein. International Journal of Biological Macromolecules, 143301. https://doi.org/10.1016/j.ijbiomac.2025.143301

  2. 2. Gupta, N. S.,Shrivastav, S. K., Singh, I. K.*, Kumari, S.,Jha, N. K.,Gupta, R. (2025).Decoding the molecular and cellular aspects of multiple sclerosis: From diagnosis to therapeutic strategies. Brain Research,1863, (149844),https://doi.org/10.1016/j.brainres.2025.149844

  3. 3. Mittal, P., Battaglin, F., Yang, Y., Soni, S., Stintzing, S., Parikh, A. R., ... Singh, I. K.*& Lenz, H. J. (2025). Genetic Polymorphisms in MHC Classes I and II Predict Outcomes in Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 26(6), 2556. https://doi.org/10.3390/ijms26062556

  4. 4. Alam, P., Arshad, M. F., & Singh, I. K. (2025). A Comprehensive Computational Approach for Identifying Estrogen Receptor Alpha Inhibitors in Breast Cancer Treatment: Integrating Biophysical Analysis and In Vitro Validation. Chemistry Select, 10(10), e202405601. https://doi.org/10.1002/slct.202405601

  5. 5. Mittal, P., Battaglin, F., Baca, Y., Xiu, J., Farrell, A., Soni, S., ... Singh, I.K* & Lenz, H. J. (2025). Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes. International Journal of Cancer, 156(8), 1583-1593. https://doi.org/10.1002/ijc.35304

  6. 6. Rustagi, V., Rameshwari, R., & Singh, I. K.* (2025). Exploring the Unexplored: Targeting MAP4K4 for Glaucoma Treatment. Current Ophthalmology Reports, 13(1), 1-9. http://dx.doi.org/10.1007/s40135-025-00329-6

  7. 7. Rustagi, V., Rameshwari, R., Singh, I. K.*, & Gupta, S. R. (2025). Absolute binding energy calculation supported with metadynamic simulation and molecular dynamics improves inhibitors identification against GSK3-? for glaucoma treatment. Molecular Simulation, 1-12. https://doi.org/10.1080/08927022.2025.2497288

  8. 8. Kumar, A., Nagar, G., Bhowmik, P., Kumari, G., Muduli, R., Das, M., ... Singh., I. K. & Majumdar, T. (2025). Protocol for designing a peptide-based multi-epitope vaccine targeting monkeypox using reverse vaccine technology. STAR protocols, 6(1), 103671. https://doi.org/10.1016/j.xpro.2025.103671

  9. 9. Singh, A., Gupta, S. R. R.,Yagnik, K. N., Dubey, S. and Singh., I. K.* (2025) In silico identification and characterization of potential allergenic proteins from Vigna mungo (blackgram). Journal of Biomolecular Structure and Dynamicshttps://doi.org/10.1080/07391102.2025.2512177

  10. 10. Rustagi, V., Gupta, S. R., Talwar, C., Singh, A., Xiao, Z. Z., Jamwal, R., ... & Singh, I.K.* (2025). SARS-CoV-2 pathophysiology and post-vaccination severity: a systematic review. Immunologic research, 73(1), 1-14. https://doi.org/10.1007/s12026-024-09553-x

  11. 11. Rustagi, V., Gupta, S. R., Singh, A., & Singh, I. K.* (2025). Beyond trial and error: Leveraging advanced software for Therapeutic discovery. Chemical Biology Letters, 12(1), 1251-1251. https://doi.org/10.62110/sciencein.cbl.2025.v12.1251

  12. 12. Sharma, P., Sharma, S., Alam, A., Alqarni, M. H., Bhardwaj, R., & Singh, I. K*. (2024). Strategic Identification of Anti-Cancer Compounds Targeting PARP15 in DNA Repair Pathways for Enhanced Therapeutic Efficacy. Polycyclic Aromatic Compounds, 1-17. https://doi.org/10.1080/10406638.2024.2413032

  13. 13. Singh P, Tabassum G, Masood M, Anwar S, Syed MA, Dev K, Hassan MI, Haque MM, Dohare R, Singh I. K*. (2024) Investigating the role of prognostic mitophagy-related genes in non-small cell cancer pathogenesis via multiomics and network-based approach. 3Biotech. 14(11):273. https://doi.org/10.1007/s13205-024-04149-6

  14. 14. Gupta, S. R., Mittal, P., Kundu, B., Singh, A., & Singh, I. K.* (2024).Silibinin: an inhibitor for a high-expressed BCL-2A1/BFL1 protein, linked with poor prognosis in breast cancer. Journal of Biomolecular Structure and Dynamics, 42(22), 12122-12132. https://doi.org/10.1080/07391102.2023.2268176

  15. 15. Gupta, S. R., Singh, S., Rustagi, V., Pahuja, M., Mangangcha, I. R., Rinchui, M., ... & Singh, I. K.* (2024). Prognostic role of TEAD4 in TNBC: in-silico inhibition of the TEAD4-YAP interaction by flufenamic acid analogs. In Silico Pharmacology, 12(2), 64. Http://dx.doi.org/10.1007/s40203-024-00239-8

  16. 16. Nagar, G., Gupta, SRR., Rustagi, V., Pramod, R.K., Singh, A., Pahuja, Singh, I. K*. (2024). Unlocking the Door for Precision Medicine in Rare Conditions: Structural and Functional Consequences of Missense ACVR1 Variants. OMICS: A Journal of Integrative Biology 28:10, 526-536https://doi.org/10.1089/omi.2024.0140

  17. 17. Alam, P., Arshad,M. F., Singh, I.K. (2024). Understanding the stability and dynamics of influenza a H5N1 polymerase PB2 CAP-Binding domain in complex with natural compounds for antiviral drug discovery. Archives of Biochemistry and Biophysics, 761:110148, https://doi.org/10.1016/j.abb.2024.110148

  18. 18. Sharma, P., Moustafa, M., Al-Shehri, M., Alotaibi, F., Bhardwaj, R., & Singh, I. K.* (2024). A simulation-based approach to target Zika virus RNA-dependent RNA polymerase with marine compounds for antiviral development. Journal of Biomolecular Structure and Dynamics, 1-11. https://doi.org/10.1080/07391102.2024.2322620

  19. 19. Jha, S. K., Nelson, V. K., Suryadevara, P. R., Panda, S. P., Pullaiah, C. P., Nuli, M. V., Kamal, M., Imran, M., Ausali, S., Abomughaid, M. M., Srivastava, R., Deka, R., Pritam, P., Gupta, N., Shyam, H. S., Singh, I. K., Dewanjee, S., Jha, N. K., Jafari, S. M. (2024) Cannabidiol and Neurodegeneration: From Molecular Mechanisms to Clinical Benefits. Ageing Research Reviews 100: 102386https://doi.org/10.1016/j.arr.2024.102386

  20. 20. Gupta, S.R.R., Ta, T.M., Khan, M., Singh, A., Singh, I.K.* and Peethambaran, B. (2023). Identification and Validation of a Small Molecule Targeting ROR1 for the Treatment of Triple Negative Breast Cancer, Frontiers in Cell and Developmental Biology,11:1243763.https://doi.org/10.3389/fcell.2023.1243763

  21. 21. Gupta, S.R.R., Garima Nagar, G., Mittal, P., Rana, S., Singh, H., Singh, R., Singh, A. and Singh. I. K.* (2023). Breast Cancer Therapeutics and Hippo Signaling Pathway: Novel MicroRNA-Gene-Protein Interaction Networks. OMICS A Journal of Integrative Biology, 27 (6): 273-280;https://doi.org/10.1089/omi.2023.0047

  22. 22. Goswami, N., Singh, A., Bharadwaj, S., Sahoo, A. K., Singh, I. K*. (2023) Targeting Neuroblastoma by Small-Molecule Inhibitors of Human ALYREF Protein: Mechanistic Insights using Molecular Dynamics Simulations. Journal of Biomolecular Structure & Dynamics. https://doi.org/10.1080/07391102.2023.2204376

  23. 23. Rustagi, V., Gupta, S.R.R., Bajaj, M., Singh, A., and Singh, I. K* (2023).PepAnalyzer: Predicting peptide properties using its sequence.Amino Acids, https://doi.org/10.1007/s00726-023-03317-x

  24. 24. Khan, M. J., Singh, P., Jha, P., Nayek, A., Malik, M. Z., Bagler, G., Kumar, B., Ponnusamy, K., Ali, Shakir, Chopra, M., Dohare, R., Singh, I. K.*, Syed, M. A. (2023) Investigating the link between miR-34a-5p and TLR6 signaling in sepsis-induced ARDS. 3Biotech, https://link.springer.com/article/10.1007/s13205-023-03700-1

  25. 25. Kumar, R., Nagar, S., Haider, S., Sood, U., Ponnusamy, K., Gauri, G. D., Anand, S., Dua, A., Singh, M., Kumar, R., Sengar, M., Singh, I. K.* and Lal, R. (2023) Monkeypox virus: phylogenomics, host-pathogen interactome and mutational cascade. Microbial Genomics, 9:000987 https://doi.org/10.1099/mgen.0.000987

  26. 26. Nagar, G., Mittal, P., Gupta, S.R.R., Pahuja, M., Sanger, M., Mishra, R., Singh A., Singh, I. K.* (2022). Multi-omics therapeutic perspective on ACVR1 gene: from genetic alterations to potential targeting. Briefings in Functional Genomics, https://doi.org/10.1093/bfgp/elac026

  27. 27. Choudhury, A., Mohammad, T., Anjum, F., Shafie, A., Singh, I. K., Abdullaev, B., Pasupuleti, V.P., Adnan, M., Yadav, D.K., Hassan M.I.* (2022) Comparative analysis of web-based programs for single amino acid substitutions of proteins. Plosone 17, 5, e0267084. https://doi.org/10.1371/journal.pone.0267084

  28. 28. Rustagi, V., Bajaj, M., Tanvi, Singh, P., Aggarwal, R., AlAjmi, M. F., Hussain, A., Hassan, M. I., Singh, A., & Singh, I. K*. (2022). Analyzing the Effect of Vaccination Over COVID Cases and Deaths in Asian Countries Using Machine Learning Models. Frontiers in Cellular and Infection Microbiology, 11. https://doi.org/10.3389/fcimb.2021.806265

  29. 29. Goswami, N., Sethi, P., AmarJyoti, Nagar, N., Gupta, S.R.R., Singh, A., Singh, I.K.* (2022) Plant-derived bioactive compounds in Neuroblastoma therapeutics: Current outlook and future perspective. Chemical Biology Letters, 9(4), 400. https://pubs.thesciencein.org/journal/index.php/cbl/article/view/400

  30. 30. Verma, P., Hassan, M. I., Singh, A., & Singh, I. K*. (2021). Design and development of novel inhibitors of aldo-ketoreductase 1C1 as potential lead molecules in treatment of breast cancer. Molecular and Cellular Biochemistry, 476(8), 2975-2987. https://doi.org/10.1007/s11010-021-04134-0

  31. 31. Sharma, P. P., Kumar, S., Kaushik, K., Singh, A., Singh, I. K., Grishina, M., Pandey, K. C., Singh, P., Potemkin, V., Poonam, Singh, G., & Rathi, B. (2021). In silico validation of novel inhibitors of malarial aspartyl protease, plasmepsin V and antimalarial efficacy prediction. Journal of Biomolecular Structure and Dynamics, 1-13.https://doi.org/10.1080/07391102.2021.1911855

  32. 32. Mittal, P., Singh, S., Sinha, R., Shrivastava, A., Singh, A., & Singh, I. K*. (2021). Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy. International Journal of Biological Macromolecules, 187, 999-1018. https://doi.org/10.1016/j.ijbiomac.2021.07.166

  33. 33. Tomar, R., Godhara, M., Lalji, R. S. K., Kumar, S., Singh, I. K*., & Shankar, B. (2021). Efficient synthesis and antibacterial activity of N-(o-benzyloxy/hydroxyphenyl) benzohydroxamic acids. Synthetic Communications, 51(21), 3299-3307. https://doi.org/10.1080/00397911.2021.1968906

  34. 34. Singh, I. K., Kumari, P., Mittal, P., Kumar, A., Singal, B., Hasan, G. M., Aggarwal, R., Kamal, M. A., Singh, A., & Hassan, M. I. (2021). Emerging Therapeutic Approaches to COVID-19. Current Pharmaceutical Design, 27(31), 3370-3388. https://doi.org/10.2174/1381612827666210125160703

  35. 35. Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K.*, Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020). Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1866(10), 165878.https://doi.org/10.1016/j.bbadis.2020.165878

  36. 36. Mittal, P., Sinha, R., Kumar, A., Singh, P., Ngasainao, M. R., Singh, A., & Singh, I. K*. (2020). Focusing on DNA Repair and Damage Tolerance Mechanisms in Mycobacterium tuberculosis: An Emerging Therapeutic Theme. Current Topics in Medicinal Chemistry, 20(5), 390-408. https://doi.org/10.2174/1568026620666200110114322

  37. 37. Kumari, P., Singh, A., Ngasainao, M. R., Shakeel, I., Kumar, S., Lal, S., Singhal, A., Sohal, S. S., Singh, I. K.*, & Hassan, M. I. (2020). Potential diagnostics and therapeutic approaches in COVID-19. Clinica Chimica Acta, 510(August), 488-497. https://doi.org/10.1016/j.cca.2020.08.013

  38. 38. Mittal, P., Singh, S., Singh, A., & Singh, I. K*. (2020). Current advances in drug delivery systems for treatment of Triple negative breast cancer (TNBC). Chemical Biology Letters, 7(1), 1-12. http://pubs.iscience.in/journal/index.php/cbl/article/view/941

  39. 39. Verma, P., Mittal, P., Singh, A., & Singh, I. K*. (2019). New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight. Anti-Cancer Agents in Medicinal Chemistry, 19. https://doi.org/10.2174/1871520619666191018172926

  40. 40. Sinha, R., Singh, P., Nath, O., Mangangcha, I. R., Kumar, A., & Singh, I. K*. (2018).Structural and functional insights into putative TAG accumulating hydrolase protein (Rv1179c) of Mycobacterium tuberculosis H37Rv. Gene Reports, 13, 66-71. https://doi.org/10.1016/j.genrep.2018.08.006

  41. 41. Nath, O., Singh, A., & Singh, I. K*. (2017). In-Silico Drug discovery approach targeting receptor tyrosine kinase-like orphan receptor 1 for cancer treatment. Scientific Reports, 7(1), 1029. https://doi.org/10.1038/s41598-017-01254-w